B. Metzler seel. Sohn & Co. AG Grows Stake in IQVIA Holdings Inc. $IQV

B. Metzler seel. Sohn & Co. AG raised its position in IQVIA Holdings Inc. (NYSE:IQV) by 62.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 32,910 shares of the medical research company’s stock after buying an additional 12,642 shares during the period. B. Metzler seel. Sohn & Co. AG’s holdings in IQVIA were worth $6,251,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of IQV. Eubel Brady & Suttman Asset Management Inc. purchased a new position in IQVIA during the third quarter worth approximately $14,278,000. Eagle Rock Investment Company LLC grew its holdings in IQVIA by 33.6% in the 3rd quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company’s stock valued at $8,800,000 after buying an additional 11,657 shares in the last quarter. OPTIMAS CAPITAL Ltd acquired a new stake in shares of IQVIA in the 3rd quarter worth $4,008,000. Amundi raised its holdings in shares of IQVIA by 46.3% during the 2nd quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock worth $210,722,000 after acquiring an additional 405,250 shares during the period. Finally, EDENTREE ASSET MANAGEMENT Ltd acquired a new position in shares of IQVIA during the 3rd quarter valued at about $7,368,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Price Performance

IQVIA stock opened at $174.56 on Monday. The company’s 50 day simple moving average is $207.22 and its 200-day simple moving average is $207.58. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04. The company has a market capitalization of $29.62 billion, a price-to-earnings ratio of 22.21, a price-to-earnings-growth ratio of 1.68 and a beta of 1.39.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. The firm had revenue of $4.36 billion during the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the company posted $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a report on Thursday, January 22nd. Jefferies Financial Group cut their price target on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, February 6th. JPMorgan Chase & Co. reduced their price target on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a research report on Friday, February 6th. UBS Group lowered their price objective on IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Finally, Royal Bank Of Canada started coverage on IQVIA in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $231.13.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.